+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Human Microbiome Market 2019-2027

  • ID: 4791802
  • Report
  • July 2019
  • Region: Global
  • 136 pages
  • Triton Market Research
1 of 4

FEATURED COMPANIES

  • Avidbiotics Corp.
  • Enterome SA
  • Metabogen AB
  • Miomics
  • Pharma
  • Second Genome
  • MORE
Market Outlook

According to this research’s research, the global human microbiome market is expected to grow with 21.89% of CAGR for the estimated period of 2019-2027.

The microbiome is a term used to describe the genes of various microbes like bacteria, fungi, protozoa and viruses that live on and in the human body. The human body hosts numerous species of microscopic organisms, and the majority of microbes lives chiefly in the human gut. The growth of the global human microbiome market owes to the rising human microbiome-based drugs and diagnostics tools used in treating various diseases. The sector provides vast opportunities for biotechnology, pharmaceuticals and diagnostics companies, thereby forecast a bright prospect.

The factors like growing prevalence for technological drug development like precision medicines and rising emphasis on early diseases detection and diagnosis drives the adoption rate of human microbiomes. Also, the global rise of chronic diseases like cancer, cardiovascular diseases, diabetes and others pushes the need for early disease detection and diagnosis, which further drives the human microbiome adoption for therapeutics. Furthermore, the rising investments by government organizations and private firms for disease detection, diagnosis and treatments are boosting the growth of the human microbiome market.

Though numerous elements drive the market, many restraints and challenges hinder the growth. Lack of awareness, technological expertise and skilled professionals pose significant limitations, eventually curbing the growth of the human microbiome market.

Regional Outlook

The human microbiome market is segmented among regions such as North America, Europe, Asia- Pacific, and Rest of World. The North America human microbiome market is surging owing to rising investments, funding and R&D activities by companies, research institutes and other organizations. On the other hand, the Europe market is flourishing as a result of growing initiatives by central government in research and development along with establishments of startups. Also, the growing funding in precision medicines and development of human microbiome drives the Asia-Pacific microbiomes market.

Competitive Outlook

The prominent players operating in the global market are Actogenix N.V., 4D Pharma, Enterome SA, Microbiome therapeutics, Miomics, Rebiotix, Second Genome, Symbiotix Biotherapies Inc., Avidbiotics Inc., Metabiomics, Vedanta Biosciences Inc. Avidbiotics Corporation, Metabogen AB, Osel Inc., Symberix Inc., and Ritter Pharmaceuticals Inc.

The number of key players in the global market is limited. However, as a result of large funding from investors and encouragement for research activities from governments, many new players are entering the market.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avidbiotics Corp.
  • Enterome SA
  • Metabogen AB
  • Miomics
  • Pharma
  • Second Genome
  • MORE
1. Global Human Microbiome Market- Summary

2. Industry Outlook
2.1. Porter’s Five Forces Outlook
2.1.1. Threat of New Entrants
2.1.2. Threat of Substitute Products or Services
2.1.3. Bargaining Power of Buyer
2.1.4. Bargaining Power of Supplier
2.1.5. Intensity of Competitive Rivalry
2.2. Key Insights
2.3. Regulatory Framework
2.4. Supply Chain Outlook
2.5. Key Buying Outlook
2.6. Estimate Outlook
2.7. Strategies in Product Development
2.8. Parent Market Outlook
2.9. Market Share Outlook
2.10. Pipeline Products
2.11. Market Drivers
2.11.1. Precision Medicines are Increasing the Adoption of Human Microbiomes
2.11.2. Rising Pervasiveness of Chronic Diseases
2.11.3. Emphasis On Early Disease Diagnosis
2.12. Market Restraints
2.12.1. Lack of Technological Expertise
2.12.2. Barriers in Initial Analysis
2.12.3. Lack of Skilled Professionals
2.12.4. Stringent Government Protocols
2.13. Market Opportunities
2.13.1. Increasing R&D Investments in Microbiome
2.13.2. Swelling Investment in New Drugs
2.13.3. Changing Lifestyles in Developed Countries
2.14. Market Challenges
2.14.1. Lack of Awareness

3. Human Microbiome Industry Outlook - By Products
3.1. Probiotics
3.2. Foods
3.3. Prebiotics
3.4. Medical Foods
3.5. Diagnostic Device
3.6. Drugs
3.7. Other Products

4. Human Microbiome Industry Outlook - By Applications
4.1. Drugs
4.2. Diagnostics

5. Human Microbiome Industry Outlook - By Diseases
5.1. Cancer
5.2. Obesity
5.3. Ulcerative Colitis
5.4. Crohn’s Disease
5.5. C. Difficle Infection
5.6. Lactose Intolerance
5.7. Dental Caries
5.8. Type 2 Diabetes
5.9. Recurrent Bacterial Vaginosis and UTI
5.10. Skin Disorders
5.11. Hyperoxaluria
5.12. Urea Cycle Disorder
5.13. Hepatic Encephalopathy
5.14. Celiac Disease
5.15. Phenylketonuria
5.16. Non-Alcoholic Steatohepatitis

6. Human Microbiome Industry – Regional Outlook
6.1. North America
6.1.1. Country Analysis
6.1.1.1. The United States
6.1.1.2. Canada
6.2. Europe
6.2.1. Country Analysis
6.2.1.1. the United Kingdom
6.2.1.2. France
6.2.1.3. Germany
6.2.1.4. Italy
6.2.1.5. Spain
6.2.1.6. Russia
6.2.1.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Country Analysis
6.3.1.1. China
6.3.1.2. India
6.3.1.3. Japan
6.3.1.4. South Korea
6.3.1.5. Australia & New Zealand
6.3.1.6. Asean Countries
6.3.1.7. Rest of Apac
6.4. Latin America
6.4.1. Country Analysis
6.4.1.1. Brazil
6.4.1.2. Mexico
6.4.1.3. Rest of Latin America
6.5. Middle East & Africa
6.5.1. Country Analysis
6.5.1.1. Saudi Arabia
6.5.1.2. Turkey
6.5.1.3. United Arab Emirates
6.5.1.4. South Africa
6.5.1.5. Rest of Middle East and Africa

7. Competitive Landscape
7.1. 4D Pharma
7.2. Avidbiotics Inc.
7.3. Actogenix N.V. (Acquired By Intrexon Corporation)
7.4. Avidbiotics Corp.
7.5. Enterome Sa
7.6. Metabiomics
7.7. Microbiome Therapeutics
7.8. Metabogen Ab
7.9. Miomics
7.10. Osel Inc.
7.11. Rebiotix
7.12. Ritter Pharmaceuticals, Inc.
7.13. Second Genome
7.14. Symberix Inc.
7.15. Symbiotix Biotherapies, Inc.
7.16. Vedanta Biosciences, Inc. (Acquired By Puretech Health Plc)

8. Methodology & Scope
8.1. Research Scope
8.2. Sources of Data
8.3. Research Methodology

Table List
Table 1 Global Human Microbiome Market By Geography 2019-2023 ($ Million)
Table 2 Global Human Microbiome Market By Geography 2023-2027 ($ Million)
Table 3 Investments in Microbiology
Table 4 Microbiome Drug Development Approaches
Table 5 Incidence of Diabetes in the Major Countries in 2016( Millions)
Table 6 Companies Working Towards Developing New Drugs
Table 7 Global Human Microbiome Market By Applications 2019-2023 ($ Million)
Table 8 Global Human Microbiome Market By Applications 2023-2027 ($ Million)
Table 9 Global Human Microbiome Market By Products 2019-2023 ($ Million)
Table 10 Global Human Microbiome Market By Products 2023-2027 ($ Million)
Table 11 Global Human Microbiome Market By Diseases 2019-2023 ($ Million)
Table 12 Global Human Microbiome Market By Diseases 2023-2027 ($ Million)
Table 13 Microbiota Associated With Cancers
Table 14 Microbiome-Based Drugs in Development For Cancer
Table 15 Microbiota Associated With Obesity
Table 16 Microbiome-Based Drugs in Development For Obesity
Table 17 Microbiota Associated With Type 2 Diabetes
Table 18 Microbiome-Based Drugs in Development For Type 2 Diabetes
Table 19 Microbiome-Based Drugs in Development For Ulcerative Colitis
Table 20 Microbiome-Based Drugs in Development For Crohn’s Disease
Table 21 Microbiome-Based Drugs in Development For Clostridium Difficle Infection
Table 22 Microbiome-Based Drugs in Development For Clostridium Difficle Infection
Table 23 Microbiome-Based Drugs in Development For Clostridium Difficle Infection
Table 24 Microbiome-Based Drugs in Development For Recurrent Bacterial Vaginosis and Urinary Tract Infection
Table 25 Microbiome-Based Drugs in Development For Skin Diseases
Table 26 Microbiome-Based Drugs in Development For Skin Diseases
Table 27 Microbiota Associated With Celiac Disease
Table 28 Microbiome-Based Drugs in Development For Celiac Disease
Table 29 Microbiome-Based Drugs in Development For Urea Cycle Disorder
Table 30 Microbiome-Based Drugs in Development For Non-Alcoholic Steatohepatitis
Table 31 Microbiome-Based Drugs in Development For Hepatic Encephalopathy
Table 32 Global Human Microbiome Market By Geography 2019-2023 ($ Million)
Table 33 Global Human Microbiome Market By Geography 2023-2027 ($ Million)
Table 34 North America Human Microbiome Market 2019-2023 ($ Million)
Table 35 North America Human Microbiome Market 2023-2027 ($ Million)
Table 36 Collective Programs By Cihr's On Human Microbiome in 2017
Table 37 Europe Human Microbiome Market 2019-2023 ($ Million)
Table 38 Europe Human Microbiome Market 2012-2026 ($ Million)
Table 39 Asia Pacific Human Microbiome Market 2019-2023 ($ Million)
Table 40 Asia Pacific Human Microbiome Market 2023-2027 ($ Million)
Table 41 Latin America Human Microbiome Market 2019-2023 ($ Million)
Table 42 Latin America Human Microbiome Market 2023-2027 ($ Million)
Table 43 Middle East and Africa Human Microbiome Market 2019-2023 ($ Million)
Table 44 Middle East and Africa Human Microbiome Market 2023-2027 ($ Million)

Figures List
Figure 1 Global Human Microbiome Market 2019-2027 ($ Million)
Figure 2 Healthcare Expenditure in the U.S. 2015-2025 (% of Gdp)
Figure 3 Research and Development Spending in the Life Science 2014-2016 ($ Billion)
Figure 4 Estimated Number of People With Chronic Conditions in United States
Figure 5 Global Human Microbiome Market in Drugs 2019-2027 ($ Million)
Figure 6 Global Human Microbiome Market in Diagnostic Device 2019-2027 ($ Million)
Figure 7 Global Human Microbiome Market in Probiotics 2019-2027 ($ Million)
Figure 8 Global Human Microbiome Market in Foods 2019-2027 ($ Million)
Figure 9 Global Human Microbiome Market in Prebiotics 2019-2027 ($ Million)
Figure 10 Global Human Microbiome Market in Medical Foods 2019-2027 ($ Million)
Figure 11 Global Human Microbiome Market in Diagnostic Device 2019-2027 ($ Million)
Figure 12 Global Human Microbiome Market in Drugs 2019-2027 ($ Million)
Figure 13 Global Human Microbiome Market in Other Products 2019-2027 ($ Million)
Figure 14 Global Human Microbiome Market in Cancer 2019-2027 ($ Million)
Figure 15 Global Human Microbiome Market in Obesity 2019-2027 ($ Million)
Figure 16 Global Human Microbiome Market in Type 2 Diabetes 2019-2027 ($ Million)
Figure 17 Global Human Microbiome Market in Ulcerative Colitis 2019-2027 ($ Million)
Figure 18 Global Human Microbiome Market in Crohn’s Disease 2019-2027 ($ Million)
Figure 19 Global Human Microbiome Market in C. Difficle Infection 2019-2027 ($ Million)
Figure 20 Global Human Microbiome Market in Lactose Intolerance 2019-2027 ($ Million)
Figure 21 Global Human Microbiome Market in Dental Caries 2019-2027 ($ Million)
Figure 22 Global Human Microbiome Market in Recurrent Bacterial Vaginosis and UTI 2019-2027 ($ Million)
Figure 23 Global Human Microbiome Market in Skin Disorders 2019-2027 ($ Million)
Figure 24 Microbes Involved in Healthy Facial Skin (Percent Microbes)
Figure 25 Global Human Microbiome Market in Hyperoxaluria 2019-2027 ($ Million)
Figure 26 Global Human Microbiome Market in Celiac Disease 2019-2027 ($ Million)
Figure 27 Global Human Microbiome Market in Urea Cycle Disorder 2019-2027 ($ Million)
Figure 28 Global Human Microbiome Market in Phenylketonuria 2019-2027 ($ Million)
Figure 29 Global Human Microbiome Market in Non-Alcoholic Steatohepatitis 2019-2027 ($ Million)
Figure 30 Global Human Microbiome Market in Hepatic Encephalopathy 2019-2027 ($ Million)
Figure 31 North America Human Microbiome Market 2019-2027 ($ Million)
Figure 32 the U.S. Human Microbiome Market 2019-2027 ($ Million)
Figure 33 Canada Human Microbiome Market 2019-2027 ($ Million)
Figure 34 Europe Human Microbiome Market 2019-2027 ($ Million)
Figure 35 the United Kingdom Human Microbiome Market 2019-2027 ($ Million)
Figure 36 France Human Microbiome Market 2019-2027 ($ Million)
Figure 37 Germany Human Microbiome Market 2019-2027 ($ Million)
Figure 38 Italy Human Microbiome Market 2019-2027 ($ Million)
Figure 39 Spain Human Microbiome Market 2019-2027 ($ Million)
Figure 40 Russia Human Microbiome Market 2019-2027 ($ Million)
Figure 41 Rest of Europe Human Microbiome Market 2019-2027 ($ Million)
Figure 42 Asia Pacific Human Microbiome Market 2019-2027 ($ Million)
Figure 43 China Human Microbiome Market 2019-2027 ($ Million)
Figure 44 India Human Microbiome Market 2019-2027 ($ Million)
Figure 45 Japan Human Microbiome Market 2019-2027 ($ Million)
Figure 46 South Korea Human Microbiome Market 2019-2027 ($ Million)
Figure 47 Australia & New Zealand Human Microbiome Market 2019-2027 ($ Million)
Figure 48 Asean Countries Human Microbiome Market 2019-2027 ($ Million)
Figure 49 Rest of Apac Human Microbiome Market 2019-2027 ($ Million)
Figure 50 Rest of World Human Microbiome Market 2019-2027 ($ Million)
Figure 51 Latin America Human Microbiome Market 2019-2027 ($ Million)
Figure 52 Brazil Human Microbiome Market 2019-2027 ($ Million)
Figure 53 Mexico Human Microbiome Market 2019-2027 ($ Million)
Figure 54 Rest of Latin America Human Microbiome Market 2019-2027 ($ Million)
Figure 55 Middle East & Africa Human Microbiome Market 2019-2027 ($ Million)
Figure 56 Saudi Arabia Human Microbiome Market 2019-2027 ($ Million)
Figure 57 Turkey Human Microbiome Market 2019-2027 ($ Million)
Figure 58 United Arab Emirates Human Microbiome Market 2019-2027 ($ Million)
Figure 59 South Africa Human Microbiome Market 2019-2027 ($ Million)
Figure 60 Rest of Middle East and Africa Human Microbiome Market 2019-2027 ($ Million)
Figure 61 Market Share Analysis of Global Human Microbiome Market 2018 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pharma
  • Avidbiotics Inc.
  • Actogenix N.V. (Acquired by Intrexon Corporation)
  • Avidbiotics Corp.
  • Enterome SA
  • Metabiomics
  • Microbiome Therapeutics
  • Metabogen AB
  • Miomics
  • Osel Inc.
  • Rebiotix
  • Ritter Pharmaceuticals, Inc.
  • Second Genome
  • Symberix Inc.
  • Symbiotix Biotherapies, Inc.
  • Vedanta Biosciences, Inc. (Acquired by Puretech Health Plc)
Note: Product cover images may vary from those shown
5 of 4

Loading
LOADING...

Adroll
adroll